Emphysematous cholecystitis

Summary

Emphysematous cholecystitis (MONDO:0005742) is a disease. A subtype of cholecystitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	emphysematous cholecystitis
Mondo ID	MONDO:0005742
MeSH	D041882
DOID	DOID:9765
ICD-11	1530167960
NCIT	C35592
SNOMED CT	95558008
UMLS	C0521610
MedGen	101072
GARD	0024225
Is cancer (heuristic)	no

Also known as: gaseous pericholecystitis

Disease family

This is a subtype of cholecystitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › non-neoplastic bile duct disorder › cholangitis › cholecystitis › emphysematous cholecystitis

Related subtypes (3): xanthogranulomatous cholecystitis, acalculous cholecystitis, acute cholecystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.